Incyte | Los Gastos De Explotación



Operating Expenses Cambio Fecha
Acadia Pharmaceuticals USD 106.1M 112.66M 2024-12
Agios Pharmaceuticals USD 115.35M 20.41M 2025-03
Alnylam Pharmaceuticals USD 576.11M 122.21M 2025-03
Amgen USD 6.86B 85M 2025-03
Biogen USD 2.12B 106.5M 2025-03
BioMarin Pharmaceutical USD 521.25M 64.65M 2025-03
Bristol-Myers Squibb USD 8.23B 3.32B 2025-03
Eli Lilly USD 7.32B 1.06B 2025-03
Exelixis USD 403.55M 82K 2025-01
Gilead Sciences USD 4.43B 687M 2025-03
Incyte USD 847.73M 29.46M 2025-03
Ionis Pharmaceuticals USD 278M 59.4M 2025-03
MacroGenics USD 35.94M 20.58M 2024-12
Merck USD 9.66B 1.67B 2025-03
Moderna USD 1.16B 1.06B 2025-03
Neurocrine Biosciences USD 485.7M 47.4M 2024-12
Novartis USD 11.28B 1.73B 2024-12
Novartis USD 10.15B 579M 2024-12
Pfizer USD 10.05B 8.12B 2025-03
PTC Therapeutics USD 205.87M 69.79M 2025-03
Regeneron Pharmaceuticals USD 2.44B 362M 2025-03
Sarepta Therapeutics USD 1.05B 548.51M 2025-03
Ultragenyx Pharmaceutical USD 282.23M 4.92M 2025-03
Vertex Pharmaceuticals USD 1.89B 230.4M 2024-12



Incyte Los Gastos De Explotación - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - May 2025.